Skip to main content
Clinical Trials/CTRI/2019/01/017089
CTRI/2019/01/017089
Recruiting
未知

A prospective, observational, Multicenter study to evAluate safety and effIcacy of cilniDipine, mEtoprolol succinate and chlorthalidoNe in high risk hypertensive patients

Aprica Healthcare Pvt Ltd0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: I10- Essential (primary) hypertension
Sponsor
Aprica Healthcare Pvt Ltd
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
Aprica Healthcare Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • 1\.Patients willing to provide written informed consent form
  • 2\.Male or Female patients aged 18 years and above
  • 3\.Essential hypertension which is uncontrolled (defined as systolic BP \>\= 140 mmHg or diastolic BP \>\= 90 mmHg ) on dual anti\-hypertensive agents
  • 4\.Patients treated with cilnidipine, metoprolol succinate and chlorthalidone

Exclusion Criteria

  • 1\. Patients receiving any other antihypertensive other than cilnidipine, metoprolol succinate and chlorthalidone

Outcomes

Primary Outcomes

Not specified

Similar Trials